BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 16490746)

  • 1. Association between phosphate removal and markers of bone turnover in haemodialysis patients.
    Albalate M; de la Piedra C; Fernández C; Lefort M; Santana H; Hernando P; Hernández J; Caramelo C
    Nephrol Dial Transplant; 2006 Jun; 21(6):1626-32. PubMed ID: 16490746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
    Ozkaya O; Buyan N; Bideci A; Gonen S; Ortac E; Fidan K; Cinaz P; Söylemezoğlu O
    Nephron Clin Pract; 2007; 105(4):c153-8. PubMed ID: 17259742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease.
    Grzegorzewska AE; Młot M
    Rocz Akad Med Bialymst; 2004; 49():190-2. PubMed ID: 15631341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones.
    Grzegorzewska AE; Młot M
    Rocz Akad Med Bialymst; 2004; 49():193-6. PubMed ID: 15631342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
    Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
    Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation.
    Fábrega E; Orive A; García-Unzueta M; Amado JA; Casafont F; Pons-Romero F
    Clin Transplant; 2006; 20(3):383-8. PubMed ID: 16824158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.
    Monegal A; Navasa M; Peris P; Alvarez L; Pons F; Rodés J; Guañabens N
    Liver Int; 2007 May; 27(4):492-7. PubMed ID: 17403189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin in men with thyroid cancer.
    Mikosch P; Igerc I; Kudlacek S; Woloszczuk W; Gallowitsch HJ; Kresnik E; Stettner H; Grimm G; Lind P; Pietschmann P
    Eur J Clin Invest; 2006 Aug; 36(8):566-73. PubMed ID: 16893379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
    Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma osteoprotegerin is associated with mortality in hemodialysis patients.
    Morena M; Terrier N; Jaussent I; Leray-Moragues H; Chalabi L; Rivory JP; Maurice F; Delcourt C; Cristol JP; Canaud B; Dupuy AM
    J Am Soc Nephrol; 2006 Jan; 17(1):262-70. PubMed ID: 16280472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
    Amato G; Mazziotti G; Sorvillo F; Piscopo M; Lalli E; Biondi B; Iorio S; Molinari A; Giustina A; Carella C
    Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.
    Martini G; Gennari L; Merlotti D; Salvadori S; Franci MB; Campagna S; Avanzati A; De Paola V; Valleggi F; Nuti R
    Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between different dialysate calcium concentrations in nocturnal hemodialysis.
    Toussaint ND; Polkinghorne KR; Kerr PG; Somerville CA; Agar JW
    Hemodial Int; 2007 Apr; 11(2):217-24. PubMed ID: 17403174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
    D'Amore M; Fanelli M; D'Amore S; Fontana A; Minenna G
    Panminerva Med; 2006 Dec; 48(4):215-21. PubMed ID: 17215793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?
    Spelling P; Bonfá E; Caparbo VF; Pereira RM
    Scand J Rheumatol; 2008; 37(6):439-44. PubMed ID: 18802807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.